Epizyme (EPZM) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Epizyme Announces Second Quarter 2016 Financial Results and Progress Against Corporate Objectives
August 8, 2016 6:30 AM EDTCompany Updates Financial Guidance Extending Runway into At Least Second Quarter of 2018
Conference Call to Be Held Today at 8:30 a.m. Eastern Time
CAMBRIDGE, Mass., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today reported financial results for the second quarter of 2016, recapped recent progress against the Companys... More
